$430 Million is the total value of CHI Advisors LLC's 18 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RPTX | Sell | REPARE THERAPEUTICS INC | $79,186,000 | +0.8% | 2,539,644 | -0.8% | 18.42% | +17.1% |
| RXDX | Sell | PROMETHEUS BIOSCIENCES INC | $70,046,000 | +33.5% | 2,852,009 | -0.8% | 16.30% | +55.1% |
| ONCR | Sell | ONCORUS INC | $23,956,000 | -2.9% | 1,735,979 | -2.0% | 5.57% | +12.9% |
| FRLN | Sell | FREELINE THERAPEUTICS HLDGSsponsored ads | $11,246,000 | -34.0% | 1,379,843 | -0.4% | 2.62% | -23.3% |
| DTIL | Sell | PRECISION BIOSCIENCES INC | $8,160,000 | +14.0% | 651,729 | -5.8% | 1.90% | +32.4% |
| KROS | Sell | KEROS THERAPEUTICS INC | $4,944,000 | -79.9% | 116,406 | -70.9% | 1.15% | -76.7% |
| OVID | Sell | OVID THERAPEUTICS INC | $854,000 | -14.2% | 218,510 | -11.7% | 0.20% | 0.0% |
| KZR | Sell | KEZAR LIFE SCIENCES INC | $796,000 | -23.3% | 146,680 | -15.8% | 0.18% | -11.1% |
| RARE | Exit | ULTRAGENYX PHARMACEUTICAL IN | $0 | – | -2,000 | -100.0% | -0.05% | – |
| BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -3,500 | -100.0% | -0.07% | – |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -40,209 | -100.0% | -0.08% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -15,000 | -100.0% | -0.12% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.